Home › Atherosclerosis › Texas › El Paso
Atherosclerosis clinical trials in El Paso, TX
4 studies for Atherosclerosis are looking for participants at sites in and around El Paso (within about 30 miles). Open a study to see who can join and how to contact the study team.
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
RecruitingPhase 3
- David Turbay, MD, El Paso
- Academy of Diabetes Thyroid and Endocrine, El Paso
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
RecruitingPhase 2/3
- Davita Clinical Research, El Paso
- DaVita Clinical Research - Horizon, El Paso
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
RecruitingPhase 3
- Research Site, El Paso
Pelacarsen Roll-over Extension Program
RecruitingPhase 3
- David Turbay MD PLLC, El Paso
About Atherosclerosis
Atherosclerosis is hardening and narrowing of the arteries caused by the buildup of a fatty substance called plaque. Learn about the risks and prevention.
More about Atherosclerosis on MedlinePlus
Atherosclerosis trials in other cities
- Boston, MA10 studies
- Houston, TX10 studies
- Washington, DC9 studies
- Hialeah, FL8 studies
- Orlando, FL8 studies
- Arlington, VA8 studies
- Dallas, TX7 studies
- Durham, NC7 studies
- Las Vegas, NV7 studies
- Memphis, TN7 studies
- Miami, FL7 studies
- Amarillo, TX6 studies
Other studies in El Paso
- Obesity10 studies
- Overweight8 studies
- Heart Failure7 studies
- Non-Small Cell Lung Cancer6 studies
- Breast Cancer6 studies
- Metastatic Cancer5 studies
- COPD5 studies
- Lung Cancer4 studies
- Cancer (all types)4 studies
- Alzheimer's Disease4 studies
- Burkitt Lymphoma4 studies
- Idiopathic Pulmonary Fibrosis4 studies
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.